FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201502418> ?p ?o ?g. }

• W3201502418 endingPage "TPS3616" @default.
• W3201502418 startingPage "TPS3616" @default.
• W3201502418 abstract "TPS3616 Background: METamp is a secondary, or co-driving, genetic change in pts with mCRC and acquired resistance to anti-EGFR therapy, which can contribute to disease progression. In EGFR-resistant pts with mCRC and METamp, MET inhibition + an anti-EGFR agent may achieve disease control by targeting emerging MET pathway activation and maintaining EGFR pathway inhibition. Tepotinib is an oral, once-daily, highly selective, potent MET tyrosine kinase inhibitor (TKI), recently approved in the US for NSCLC harboring MET exon 14 skipping. Tepotinib + gefitinib demonstrated improved outcomes in pts with EGFR-mutant METamp NSCLC and acquired EGFR TKI resistance vs chemotherapy (INSIGHT: NCT01982955). In these pts, progression-free survival (PFS) was 16.6 vs 4.2 months (HR = 0.13; 90% CI: 0.04, 0.43) and overall survival (OS) was 37.3 vs 13.1 months (HR = 0.08; 90% CI: 0.01, 0.51). In pts with mCRC and acquired resistance to anti-EGFR antibody therapy due to METamp, tepotinib + anti-EGFR antibody cetuximab may be active and provide an effective therapeutic option. Methods: This Phase II, multicenter, single-arm, open-label study will assess preliminary safety and tolerability, antitumor activity, and explore pharmacokinetic (PK) profiles of tepotinib + cetuximab in pts with RAS/BRAF wild-type left-sided mCRC and acquired resistance to anti-EGFR antibody-targeted therapy due to METamp (NCT04515394). A safety run-in (6–12 pts) will evaluate the recommended Phase II dose of tepotinib to be used in combination with cetuximab (endpoint: dose-limiting toxicities). Enrollment is based on a confirmed advanced left-sided CRC diagnosis ( RAS/BRAF wild-type), documented previous anti-EGFR therapy and acquired resistance on most recent anti-EGFR antibody and METamp confirmed by liquid and/or tissue biopsy. Pts must be ≥18 years old, have ECOG PS of 0/1 and normal organ function. The study will screen sufficient pts to account for setting-specific heterogenecity in reported METamp incidence. Approximately 42 pts are planned to receive study treatment: ̃22 in Cohort A (second-line, outside US) and 20 in Cohort B (≥third-line, US only). Primary endpoint: investigator-assessed objective response (RECIST 1.1). Secondary endpoints are investigator-assessed duration of response (DoR), PFS (RECIST 1.1) and OS, tolerability and safety (NCI-CTCAE v5.0), and cetuximab immunogenicity (measured by antidrug antibody assays at the start and end of treatment). Additional endpoints include assessment of tepotinib and cetuximab PK profiles, and expression of biomarkers of resistance (from blood and/or tissue samples). Retrospective assessment of best overall response, DoR and PFS by an independent review committee may be conducted. No formal statistical hypothesis will be tested in this exploratory study. Clinical trial information: NCT04515394." @default.
• W3201502418 created "2021-09-27" @default.
• W3201502418 creator A5000928175 @default.
• W3201502418 creator A5013909542 @default.
• W3201502418 creator A5015509025 @default.
• W3201502418 creator A5020893157 @default.
• W3201502418 creator A5028514396 @default.
• W3201502418 creator A5029413426 @default.
• W3201502418 creator A5030186225 @default.
• W3201502418 creator A5032970786 @default.
• W3201502418 creator A5052288114 @default.
• W3201502418 creator A5056328676 @default.
• W3201502418 creator A5074891676 @default.
• W3201502418 creator A5077985050 @default.
• W3201502418 creator A5082347575 @default.
• W3201502418 creator A5082744239 @default.
• W3201502418 creator A5085704487 @default.
• W3201502418 creator A5090645179 @default.
• W3201502418 date "2021-05-20" @default.
• W3201502418 modified "2023-09-26" @default.
• W3201502418 title "PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp)." @default.
• W3201502418 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.tps3616" @default.
• W3201502418 hasPublicationYear "2021" @default.
• W3201502418 type Work @default.
• W3201502418 sameAs 3201502418 @default.
• W3201502418 citedByCount "1" @default.
• W3201502418 countsByYear W32015024182023 @default.
• W3201502418 crossrefType "journal-article" @default.
• W3201502418 hasAuthorship W3201502418A5000928175 @default.
• W3201502418 hasAuthorship W3201502418A5013909542 @default.
• W3201502418 hasAuthorship W3201502418A5015509025 @default.
• W3201502418 hasAuthorship W3201502418A5020893157 @default.
• W3201502418 hasAuthorship W3201502418A5028514396 @default.
• W3201502418 hasAuthorship W3201502418A5029413426 @default.
• W3201502418 hasAuthorship W3201502418A5030186225 @default.
• W3201502418 hasAuthorship W3201502418A5032970786 @default.
• W3201502418 hasAuthorship W3201502418A5052288114 @default.
• W3201502418 hasAuthorship W3201502418A5056328676 @default.
• W3201502418 hasAuthorship W3201502418A5074891676 @default.
• W3201502418 hasAuthorship W3201502418A5077985050 @default.
• W3201502418 hasAuthorship W3201502418A5082347575 @default.
• W3201502418 hasAuthorship W3201502418A5082744239 @default.
• W3201502418 hasAuthorship W3201502418A5085704487 @default.
• W3201502418 hasAuthorship W3201502418A5090645179 @default.
• W3201502418 hasConcept C121608353 @default.
• W3201502418 hasConcept C126322002 @default.
• W3201502418 hasConcept C143998085 @default.
• W3201502418 hasConcept C197934379 @default.
• W3201502418 hasConcept C203092338 @default.
• W3201502418 hasConcept C2776999253 @default.
• W3201502418 hasConcept C2777506169 @default.
• W3201502418 hasConcept C2778375690 @default.
• W3201502418 hasConcept C2779438470 @default.
• W3201502418 hasConcept C2779998722 @default.
• W3201502418 hasConcept C2780580887 @default.
• W3201502418 hasConcept C526805850 @default.
• W3201502418 hasConcept C535046627 @default.
• W3201502418 hasConcept C71924100 @default.
• W3201502418 hasConceptScore W3201502418C121608353 @default.
• W3201502418 hasConceptScore W3201502418C126322002 @default.
• W3201502418 hasConceptScore W3201502418C143998085 @default.
• W3201502418 hasConceptScore W3201502418C197934379 @default.
• W3201502418 hasConceptScore W3201502418C203092338 @default.
• W3201502418 hasConceptScore W3201502418C2776999253 @default.
• W3201502418 hasConceptScore W3201502418C2777506169 @default.
• W3201502418 hasConceptScore W3201502418C2778375690 @default.
• W3201502418 hasConceptScore W3201502418C2779438470 @default.
• W3201502418 hasConceptScore W3201502418C2779998722 @default.
• W3201502418 hasConceptScore W3201502418C2780580887 @default.
• W3201502418 hasConceptScore W3201502418C526805850 @default.
• W3201502418 hasConceptScore W3201502418C535046627 @default.
• W3201502418 hasConceptScore W3201502418C71924100 @default.
• W3201502418 hasIssue "15_suppl" @default.
• W3201502418 hasLocation W32015024181 @default.
• W3201502418 hasOpenAccess W3201502418 @default.
• W3201502418 hasPrimaryLocation W32015024181 @default.
• W3201502418 hasRelatedWork W1571296368 @default.
• W3201502418 hasRelatedWork W1835621121 @default.
• W3201502418 hasRelatedWork W1971492107 @default.
• W3201502418 hasRelatedWork W2017982166 @default.
• W3201502418 hasRelatedWork W2023373067 @default.
• W3201502418 hasRelatedWork W2026836017 @default.
• W3201502418 hasRelatedWork W2097900911 @default.
• W3201502418 hasRelatedWork W2561259078 @default.
• W3201502418 hasRelatedWork W2784706285 @default.
• W3201502418 hasRelatedWork W2889523320 @default.
• W3201502418 hasVolume "39" @default.
• W3201502418 isParatext "false" @default.
• W3201502418 isRetracted "false" @default.
• W3201502418 magId "3201502418" @default.
• W3201502418 workType "article" @default.